The Reserve Bank of India (RBI) rejects Religare’s proposal to demerge its businesses, according to reports citing the regulator’s decision. The development comes despite the proposal receiving “exchange nod,” indicating that at least some stock-exchange procedural requirements were met or acknowledged prior to the RBI’s ruling. Multiple outlets report that the RBI does not provide detailed, publicly disclosed reasons for rejecting the demerger plan. As a result, the specific regulatory concerns or conditions that led to the rejection are not stated in the available coverage. The decision effectively halts the proposed corporate restructuring under the current terms, leaving Religare to reassess its next steps and potentially submit revised plans if permitted under applicable regulatory guidance. The reports focus on the fact of rejection and the absence of disclosed justification by the RBI, rather than providing additional information about the internal structure of the proposed demerger or any alternative proposals.
RBI rejects Religare demerger proposal despite exchange approval
The Reserve Bank of India (RBI) rejects Religare’s proposal to demerge its businesses, according to reports citing the regulator’s decision. The development comes despite the proposal receiving “excha...
- The RBI rejects Religare’s demerger proposal.
- The rejection occurs despite prior stock-exchange approval or “exchange nod.”
- The RBI does not publicly disclose specific reasons for rejecting the proposal.
- The demerger plan is effectively stopped under the current proposal.
The regulator has not disclosed the specific reasons for rejecting the proposal
1 hour ago
US jobs data lowers odds of September Fed rate hike, futures markets show
US hiring and labor-market data released for July lead markets to cut their expectations for a Federal Reserve rate hike...
Vertex, Biogen, Amgen and other biopharma firms report 2026 Q2 earnings on conference calls
In 2026 Q2 earnings calls and related summaries, multiple biopharmaceutical companies—including Vertex Pharmaceuticals,...
Earnings calls from multiple U.S. financial firms report second-quarter 2026 results
Multiple U.S. financial institutions hold second-quarter 2026 earnings calls and publish results presentations or call s...